Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board

Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that Professors Arshed Quyyumi, MD, FRCP, FACC and Javed Butler, MD, MPH, FACC, FAHA of the Emory Clinical Cardiovascular Research Institute have agreed to join the Scientific Advisory Board for Stemedicas Cardiology Division.

San Diego, CA (PRWEB) April 22, 2013

Dr. Arshed A. Quyyumi has been involved in clinical translational research in cardiovascular diseases for over 25 years. His research focuses on vascular biology, angiogenesis, progenitor cell biology, mechanisms of myocardial ischemia, and the role of genetic and environmental risks on vascular disease. In 2001 he was appointed Professor of Medicine in the Division of Cardiology at the Emory University School of Medicine. In 2010, he was named Co-Director of the Emory Clinical Cardiovascular Research Institute (ECCRI). Dr. Quyyumi serves on the editorial boards of several national journals and is a reviewer for the National Institute of Healths (NIH) National Heart, Lung and Blood Institute Study Sections. Dr. Quyyumi has authored more than 220 peer-reviewed publications and has been an invited speaker and session chair at many scientific meetings and conferences. During his academic career, Dr. Quyyumi has managed more than 50 NIH, industry-funded, or investigator-initiated projects, including numerous clinical trials.

Dr. Javed Butlers research focuses on the disease progression, outcomes, and prognosis determination in patients with heart failure, with special emphasis on patients undergoing cardiac transplantation and left ventricular assist device placement. Before moving to Emory University where he is a professor of cardiology, he was Director for the Heart and Heart-Lung Transplant programs at Vanderbilt University. He also serves as the Deputy Chief Science Advisor for the American Heart Association. Additionally, he serves various editorial responsibilities for the Journal of the American College of Cardiology, Journal of Cardiac Failure, American Heart Journal, Journal of the American College of Cardiology Heart Failure, Heart Failure Clinics, Current Heart Failure Report, and Congestive Heart Failure. He is board certified in Cardiology, Internal Medicine, Advanced Heart Failure and Transplantation Medicine, and Nuclear Cardiology. Dr. Butler also serves on the Executive Council of the Heart Failure Society of America. He has published over 175 peer reviewed papers and has participated in over 50 federally funded and non-federally funded clinical trials. He has served on several steering committees, events committees and data safety monitoring committees for multi-center clinical trials.

Stephen Epstein, M.D., Chairman of the Medical & Scientific Advisory Board for Stemedicas Cardiology Division, commented, I am delighted to welcome Drs. Quyyumi and Butler to the cardiology team. I believe our collective breadth of experience will provide Stemedica with both perspective and direction as the company expands its efforts in cardiovascular medicine.

Stemedica recently formed its Cardiology Division due to the considerable progress in the translational application of its ischemia tolerant adult allogeneic stem cells for cardiovascular diseases. The Company gained FDA approval for a multi-center Phase II clinical trial for intravenous treatment of AMI with its Stemedyne MSC product. Regulatory approval has also been granted to the National Medical Research Center in Astana, Kazakhstan for a Phase III trial with Stemedyne MSC. A Phase II clinical trial for chronic heart failure has begun at Hospital Angeles in Mexico. The Cardiology Division Scientific Advisory Board was organized to support these and future efforts.

Sergey Sikora, Ph.D., M.D., President of Stemedicas Cardiovascular Division noted, Emory has been one of the leaders in cardiology and we are honored to have physicians of Drs. Quyyumi and Butlers statures participate with us in cardiovascular translational medicine.

Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica commented, We are pleased by the impressive and promising outcomes that Stemedicas adult stem cells are experiencing in cardiology. We view this area as critical for the success of Stemedica and have worked diligently to get the best experts to advise us in this field.

About Stemedica Cell Technologies, Inc. http://www.stemedica.com

Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company that is committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for clinical trials in ischemic stroke, cutaneous photoaging and myocardial infarct. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

Visit link:
Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board